Skip to main content

Tysabri Disease Interactions

There are 4 disease interactions with Tysabri (natalizumab).

Major

Immunosuppressive agents (applies to Tysabri) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

References

  1. "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories (2001):
  2. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc (2007):
  3. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline (2011):
  4. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb (2011):
  5. "Product Information. Aubagio (teriflunomide)." Genzyme Corporation (2012):
  6. "Product Information. Tecfidera (dimethyl fumarate)." Biogen (2013):
  7. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
  8. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):
  9. "Product Information. Gamifant (emapalumab)." Sobi Inc (2018):
  10. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
  11. "Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals (2021):
View all 11 references
Major

Immunosuppressive agents (applies to Tysabri) PML

Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.

References

  1. "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories (2001):
  2. "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc (2004):
  3. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc (2007):
  4. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline (2011):
  5. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb (2011):
  6. "Product Information. Aubagio (teriflunomide)." Genzyme Corporation (2012):
  7. "Product Information. Tecfidera (dimethyl fumarate)." Biogen (2013):
  8. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
  9. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):
View all 9 references
Moderate

Natalizumab (applies to Tysabri) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Postmarketing reports have associated the use of natalizumab with severe hepatic toxicity, including acute liver failure requiring transplant. Natalizumab should be discontinued in patients with jaundice or other evidence of significant liver injury and appropriate therapy should be instituted according to clinical guidelines.

References

  1. "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc (2004):
Moderate

Natalizumab (applies to Tysabri) meningitis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Herpes Zoster Meningitis

Natalizumab increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses. It is recommended to monitor patients receiving natalizumab for signs and symptoms of meningitis and encephalitis. If herpes encephalitis or meningitis occurs, treatment should be discontinued, and appropriate treatment for herpes encephalitis/meningitis should be administered.

References

  1. "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc (2004):

Tysabri drug interactions

There are 349 drug interactions with Tysabri (natalizumab).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.